Biopharmaceutical research and metabolic therapy by Altimmune
Altimmune joins Goldman Sachs Global Healthcare Conference with June 10 fireside chat in Miami
Altimmune is participating in the Goldman Sachs 47th Annual Global Healthcare Conference, which is currently underway in Miami. The company will host a fireside chat on June 10 at 8 am ET as ...
Altimmune convenes biopharma leaders at Jefferies Healthcare Conference in New York
Altimmune will participate in the Jefferies Healthcare Conference in New York City, bringing together company leadership for a fireside chat on June 4 at 12:50 pm ET. The event positions ...
Altimmune heads to Barcelona for EASL26 to engage global liver disease specialists
Altimmune is set to participate in EASL26 in Barcelona, connecting with the international liver disease community. The company invites attendees to visit its Medical Affairs team at booth D-40 ...
Altimmune reports first quarter 2026 results update
Altimmune has released its financial results for the first quarter of 2026. The company has provided further information and documentation on its website, giving investors and stakeholders ...
Altimmune urges earlier clinical action on alcohol use disorder and liver disease link
Altimmune draws attention to the often-overlooked connection between alcohol use disorder and serious liver diseases, calling for a more proactive approach in addressing these intertwined health ...
Altimmune launches education drive linking alcohol and liver health
Altimmune is intensifying efforts on education around the relationship between alcohol consumption and liver health during Alcohol Awareness Month. The company is simultaneously progressing new ...
Altimmune appoints Luis Sanay as vice president of investor relations to strengthen financial communications
Altimmune has announced the appointment of Luis Sanay as vice president of investor relations. The company expects Sanay, who brings 15 years of experience in investor relations and financial ...
Fireside chat set for Leerink Global Healthcare Conference, Altimmune announces
Altimmune will hold a fireside chat at the upcoming Leerink Global Healthcare Conference on March 11. The company has directed interested parties to its Events page for further details. This ...
Altimmune joins Citizens Life Sciences Conference for fireside chat in Miami Beach
Altimmune is set to take part in a fireside chat at the Citizens Life Sciences Conference in Miami Beach. The event is scheduled for March 10 at 2:15pm ET, with further details available on the ...
Altimmune CEO Jerry Durso strengthens company foundation for liver disease mission
Altimmune, led by CEO Jerry Durso, is focusing on strengthening the foundational operations of the organization to further its mission of advancing treatments for serious liver diseases. In a ...
Altimmune releases positive results from MASH dual receptor trial
Altimmune has announced promising 48-week topline results from their IMPACT Phase 2b trial on an investigational glucagon/GLP-1 dual receptor agonist in treating MASH. The company believes this ...
Altimmune announces leadership change as CEO Vipin Garg steps down
Altimmune has announced a significant leadership change as CEO Vipin Garg, Ph.D. steps down after transforming the company over seven years into an agile, clinical-stage entity. Jerry Durso, the ...
Altimmune's IMPACT study data published in The Lancet
Altimmune has announced that the 24-week data from their IMPACT Phase 2b study in patients with MASH has been published in The Lancet. The study results, which mark a significant development in ...
Altimmune completes enrollment for Phase 2 trial in AUD study
Altimmune has announced the completion of enrollment for its RECLAIM Phase 2 trial focused on alcohol use disorder (AUD). This marks a significant step forward in advancing their research in ...
Altimmune joins experts to examine MASH landscape
Altimmune participates in the MOSAIC Multi-Stakeholder Think Tank alongside experts from Inventiva, Merck, and Sagimet Biosciences. Dr. Scott Harris of Altimmune is set to join a moderated ...
